1 / 22

Dr Andrew Dodgson Consultant Microbiologist and Infection Control Doctor

Carbapenemases in practice - lessons learnt from spread in our patch, prophylaxis and first/second line treatments. Dr Andrew Dodgson Consultant Microbiologist and Infection Control Doctor Health Protection Agency & Central Manchester University Hospitals NHS Foundation Trust. Carbapenemases.

vahe
Download Presentation

Dr Andrew Dodgson Consultant Microbiologist and Infection Control Doctor

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Carbapenemases in practice - lessons learnt from spread in our patch, prophylaxis andfirst/second line treatments Dr Andrew Dodgson Consultant Microbiologist and Infection Control Doctor Health Protection Agency & Central Manchester University Hospitals NHS Foundation Trust

  2. Carbapenemases • Phenotypically similar enzymes • Genotypically diverse • Epidemiologically Diverse

  3. Classification • Class A (serine based) • KPC, GES, SME, NMC, IMI • Class B (metallo-enzymes) • NDM, IMP, VIM, GIM, SIM, SMP, L1, BCII, Ccra • Class D (serine) • OXA From Queenan and Bush, CMR 2007

  4. Chromosomal Class A SME, NMC, IMI Class B BCII, L1, Ccra Plasmid Class A KPC, GES Class B NDM, IMP Class D OXA Classification From Queenan and Bush, CMR 2007

  5. “Transmission” of Resistance • Clonal spread (particularly ST258 K. pneumofor KPC) • Transmission of plasmid • Other enterobacteriaceae implicated, e.g. Enterobacter, E.coli

  6. Therapy • Need to know local epidemiology • i.e. clonal spread • all isolates have the same antibiogram • or polyclonal, transmission of plasmid • sensitivities vary depending on the background of the strain carrying the plasmid

  7. Local situation? • Many different strains • Same plasmid E. coli Enterobacter KPC producer from a nearby hospital Courtesy N. Woodford

  8. Carbapenems? • Some carbapenemase producers will have MIC’s below the breakpoint for resistance Carmeli et al. CMI 2010

  9. Miriagou et al. CMI 2010.

  10. Carbapenems? • Somecarbapenemase producers will have MIC’s below the breakpoint for resistance • Carbapenems show some activity in animal models against these strains • Strong inoculum effect noted in in-vitro models • MIC ≤8 Mortality 29%, MIC>8 75% Carmeliet al. CMI 2010; Daikoset al, AAC 2009

  11. Other options • Again, depends on susceptibility results. • Many strains multi (or almost pan-) resistant

  12. Other options • Quinolones • Aminoglycosides • Tigecycline • Colistin • Trimethoprim • Fosfomycin • Temocillin • Combinations (which ones?)

  13. What should we do? • Review of 298 published cases (244 BSI) Tzouvelekiset al, CMR 2011

  14. Sensitivities • Data from 30 Blood cultures

  15. What do we do? • Plasmid mediated resistance • Necessitates individual patient approach • Usually based on sensitivities of previous screening or clinical isolates • Some broad principles: • 2 agents • B-lactam (if poss) • Aminoglycoside if possible • Colistin never alone

  16. Prophylaxis • Difficult to generalise due to variable susceptibilities • GI Surgery • Tigecycline • Urology • Aminoglycoside or Cipro

  17. Empiric Rx • Paedsneutropenic sepsis: • Pip/Taz and Amikacin 1st line • Close scrutiny of sens of all BC’s • And sens of CPC screening isolates • No Amik resistance (yet)

  18. Empiric Rx • GNR in blood culture, pt known to be colonised • Depends on sens and site of primary infection • Toxicity often less of a concern (due to lack of options) • Almost always add suitable aminoglycoside • Tige/Colistin not used alone

  19. Empiric Rx • What have we done? • 30 bacteraemic adult pt’s • 18 different regimes used • 11 received monotherapy (cip 4, gent 4, tige, col, mero) • 15 had 2 Abx, 1 had 3 and 1 4. • 16 of 19 with 2 or more abx had an aminoglycoside

  20. Summary • Carbapenemase producing enterobacteriaceaeare heterogenous • Know your local epidemiology • Take MIC’s into account (esp. Carb’s) • Be prepared to think laterally

  21. Acknowledgements • Dr Louise Sweeney • Dr Barry Neish • All the Micro staff at CMFT • Prof Neil Woodford

More Related